反应详情

Essentially prepared according to Procedure H using tert-butyl 4-(4-chloro-5,7-difluoro-3-methylquinolin-2-yl)piperazine-1-carboxylate (85.0 mg, 0.210 mmol) and 5-morpholinopyridin-3-amine in toluene to give tert-butyl 4-(5,7-difluoro-3-methyl-4-(5-morpholinopyridin-3-ylamino)quinolin-2-yl)piperazine-1-carboxylate. 1H NMR (CDCl3) δ ppm 7.93 (1H, d, J=2.3 Hz), 7.70 (1H, d, J=2.2 Hz), 7.29 (1H, ddd, J=10.0, 2.5, 1.2 Hz), 6.90 (1H, d, J=12.9 Hz), 6.80 (1H, ddd, J=13.8, 8.8, 2.6 Hz), 6.57 (1H, t, J=2.3 Hz), 3.85 (4H, dd, J=5.6, 4.0 Hz), 3.52-3.63 (4H, m), 3.27-3.35 (4H, m), 3.10-3.17 (4H, m), 2.07 (3H, s), 1.50 (9H, s). Mass Spectrum (ESI) m/e=541.3 (M+1).

1. customEssentially prepared